NCT05248555

Brief Summary

The National Australian HCV Point-of-Care Testing Program will establish an observational cohort to evaluate whether scale-up of finger-stick point-of-care HCV testing increases diagnosis and treatment for HCV infection. Participants will be recruited from settings providing services to people with a risk factor for the acquisition of HCV infection (including drug treatment clinics, needle and syringe programs, homelessness settings, mental health services, prisons, and mobile outreach). All participants who undergo HCV point-of-care testing at the study site will be included in the data collection. Participants will not receive treatment as a part of this study. Participants who are HCV RNA positive will be linked to standard of care.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40,000

participants targeted

Target at P75+ for all trials

Timeline
7mo left

Started Dec 2021

Longer than P75 for all trials

Geographic Reach
1 country

11 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress89%
Dec 2021Dec 2026

Study Start

First participant enrolled

December 1, 2021

Completed
11 days until next milestone

First Submitted

Initial submission to the registry

December 12, 2021

Completed
2 months until next milestone

First Posted

Study publicly available on registry

February 21, 2022

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2024

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Expected
Last Updated

June 13, 2024

Status Verified

June 1, 2024

Enrollment Period

3 years

First QC Date

December 12, 2021

Last Update Submit

June 11, 2024

Conditions

Keywords

Hepatitis C Virus

Outcome Measures

Primary Outcomes (1)

  • The proportion of HCV infected participants who initiate HCV treatment at 12 weeks

    To evaluate the proportion of HCV infected (HCV RNA quantifiable) participants who initiate HCV treatment at 12 weeks following finger-stick point-of-care HCV RNA testing.

    12 Weeks from enrolment

Secondary Outcomes (7)

  • The proportion of participants who accept point-of-care testing

    2 years from recruitment commencement

  • The prevalence of HCV infection amongst study participants tested

    2 years from recruitment commencement

  • To evaluate the time to HCV treatment uptake among HCV RNA positive participants

    52 weeks

  • To evaluate proportion of HCV RNA positive participants who initiate HCV treatment

    52 weeks

  • To evaluate the proportion of participants who complete HCV (DAA) treatment

    52 weeks

  • +2 more secondary outcomes

Study Arms (1)

People at risk of HCV acquisition

Clinic staff will offer HCV point-of-care testing to participants as they access services. Testing will be performed using point-of-care HCV RNA testing.

Diagnostic Test: Point-of-Care Testing

Interventions

Point-of-Care TestingDIAGNOSTIC_TEST

Participants will be offered finger-stick point-of-care testing for HCV

People at risk of HCV acquisition

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Participants will be recruited from settings that provide services to people with a risk factor for the acquisition of HCV infection, including drug treatment clinics, needle and syringe programs, prisons, mobile outreach services, community health services, mental health services, homelessness services, and other appropriate settings nationally. It is anticipated approximately 40,000 participants will be screened for HCV infection using point-of-care HCV testing.

You may qualify if:

  • ≥ 18 years of age.
  • Received point-of-care HCV testing.

You may not qualify if:

  • Nil

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (11)

Justice Health and Forensic Mental Health Network

Sydney, New South Wales, Australia

NOT YET RECRUITING

Lotus Glen Correctional Centre

Cairns, Queensland, Australia

RECRUITING

Hepatitis Queensland

Coorparoo, Queensland, 4151, Australia

NOT YET RECRUITING

West Moreton Hospital and Health Service

Ipswich, Queensland, Australia

RECRUITING

Townsville Correctional Centre

Townsville, Queensland, Australia

RECRUITING

Woodford Correctional Centre

Woodford, Queensland, Australia

RECRUITING

South Australian Prison Health Service

Marden, South Australia, 5070, Australia

NOT YET RECRUITING

Mount Gambier Priosn

Mount Gambier, South Australia, 5290, Australia

NOT YET RECRUITING

St Vincent's Correctional Health Services

Fitzroy, Victoria, 3065, Australia

NOT YET RECRUITING

Medically Supervised Injecting Room

Melbourne, Victoria, 3000, Australia

NOT YET RECRUITING

Geo Healthcare - The Geo Group Australia Pty Ltd

Ravenhall, Victoria, 3023, Australia

NOT YET RECRUITING

MeSH Terms

Conditions

Hepatitis C

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsHepatitis, Viral, HumanVirus DiseasesFlaviviridae InfectionsRNA Virus InfectionsHepatitisLiver DiseasesDigestive System Diseases

Central Study Contacts

Simon Comben, BSc, MN

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 12, 2021

First Posted

February 21, 2022

Study Start

December 1, 2021

Primary Completion

December 1, 2024

Study Completion (Estimated)

December 1, 2026

Last Updated

June 13, 2024

Record last verified: 2024-06

Locations